Home>Topics>Funds>SPDR S&P Biotech

SPDR S&P Biotech

  1. All
  2. Commentary
  3. ETF Reports
  4. Headlines
  1. Dynamic And Durable Growth (Part 1)

    Headlines

    Thu, 24 Jul 2014

    By Invesco : By Janet Luby Part 1: A Biotech/Pharma Revolution This is the first in a four-part series examining dynamic and durable growth themes that affect the U.S. economy and may present opportunities for investors. The remaining three blog posts will examine the enormous implications of shale

  2. Today's Market: Biotech Names Rallying Today

    Headlines

    Wed, 23 Jul 2014

    players in the sector by buying ETFs, such as the SPDR S & P Biotech ETF (NY XBI ) and the iShares Nasdaq Biotechnology (NASDAQ: IBB ) with our preference being the SPDR S & P Biotech due to it having less exposure to the more speculative

  3. Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?

    Headlines

    Mon, 21 Jul 2014

    By DoctoRx : Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed. Biogen Idec (NASDAQ: BIIB ) fell more than 7% after that statement. Gilead Sciences (NASDAQ: GILD ) fell 5% peak-to-trough. Small ones got dumped big-time. Is it but a passing ...

  4. This week's selloff looking like March's

    Headlines

    Tue, 8 Jul 2014

    which led March's "momo" selloff, among them the biotechs ( XBI -4.5% ) and social media ( SOCL -4.4% ). Also familiar ..... and he suggests investors begin raising cash. Biotech ETFs: XBI , BBH , FBT , PBE Low-vol ETFs: SPLV , LGLV , CFA , CFO Utility

  5. IHE iShares US Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 5 May 2014

    tracking other health-care subsectors show numbers in the 20% to 25% range. For instance, the equal-weight SPDR S & P Biotech XBI has a five-year volatility of return of 24.5%. Meanwhile, the market-cap-weighted iShares US Healthcare

  6. XPH SPDR S&P Pharmaceuticals ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 5 May 2014

    tracking other health-care subsectors show numbers in the 16% to 25% range. For instance, the equal-weight SPDR S & P Biotech XBI has a five-year volatility of return of 24.2%. Meanwhile, the market-cap-weighted iShares US Healthcare

  7. T/A May 2014 -- SPY "Home On The Range"

    Commentary

    Wed, 30 Apr 2014

    Some plays like XLI are still Bullish. Momentum stocks as represented by QQQ and XBI have broken down and are in a Bearish IT for now. My computer considers her XBI trade management as the “Greatest Escape Since Dunkirk” but she tends to be

  8. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Wed, 16 Apr 2014

    cheaper ETF options exist. For instance, both SPDR S & P Biotech XBI and Market Vectors Biotech ETF BBH charge just 0 ..... seeking exposure solely to biotechs also can consider SPDR S & P Biotech XBI (0.35% expense ratio), which is a fairly concentrated

  9. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Wed, 16 Apr 2014

    these products in the U.S. XBI 's 0.35% expense ratio is ..... like Amgen and Celgene. Thus, XBI 's average market cap, on ..... the industry in one trade. SPDR S & P Biotech offers exposure to the promising ..... focus, investors should view XBI as a specialty satellite holding

  10. FBT First Trust NYSE Arca Biotech Index ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Wed, 16 Apr 2014

    relative to other biotech ETFs--in particular, SPDR S & P Biotech XBI , which charges 0.35%. FBT's estimated holding ..... biotech companies can consider four other ETFs. SPDR S & P Biotech XBI (0.35% expense ratio) holds a fairly concentrated

« Prev123Next »
Content Partners